Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells

Abstract

Effective B cell responses such as cytokine secretion, proliferation, and Ab-specific responses are essential to clear hepatitis B virus (HBV) infection. However, HBV alters numerous immune pathways to persist in the host. B cell activity depends on activation of the innate sensor TLR9 by viral or bacterial DNA motifs. How HBV can deregulate B cell functions remains unknown. In this study, we show that HBV can enter and decrease TLR9 expression in human primary B cells. Using PBMCs from human blood donors, we show that TLR9 expression was reduced in all peripheral B cells subsets exposed to HBV. B cell function mediated by TLR9, but not TLR7, such as proliferation and proinflammatory cytokines secretion, were abrogated in the presence of HBV; however, global Ig secretion was not downregulated. Mechanistically, we show, using human myeloma B cell line RPMI 8226, that the surface Ag hepatitis B surface Ag was responsible for TLR9 dysfunction. hepatitis B surface Ag suppressed the phosphorylation and thus the activation of the transcription factor CREB, preventing TLR9 promoter activity. Finally, we corroborated our in vitro findings in a cohort of chronic HBV carriers and found that TLR9 expression and function were significantly suppressed. The effect of HBV on TLR9 activity in B cells gives insights into oncoviral immune escape strategies, providing knowledge to develop novel immunotherapeutic approaches in chronic HBV-carrier patients.

Immunothrombosis in COVID-19: Implications of Neutrophil Extracellular Traps

“…These receptors are activated when they recognize structures that are not normally present in the host cells and/or that are shared by multiple pathogens (including viruses) [ 32 ]. A variety of TLRs have been specifically identified for different infectious agents, such as types 4, 7, 8, and 9 [ 25 , 29 , 33 ].…”

The Multiple Functions of B Cells in Chronic HBV Infection

“…In addition, these antiviral treatments are commonly used in two of the four clinical stages of chronic HBV infection: 1) immune activity (HBeAg-positive hepatitis); and 2) HBeAg negative hepatitis. In almost all patients with chronic HBV infection, these therapies display high efficacy, including disturbed B cell homeostasis, can be partially recovered ( 124 ); however, difficulties remain in achieving a loss of HBsAg and functional cure (persistently undetectable HBsAg) ( 125 ). A high load of HBsAg could further inhibit adaptive immune function and ultimately leads to specific tolerance that prevents patients from eradicating HBV infection.…”

Endothelial Nox2 Limits Systemic Inflammation and Hypotension in Endotoxemia by Controlling Expression of Toll-Like Receptor 4

“…These differences may be explained by distinct transcriptional regulation mechanisms among TLRs. Sp1/Sp3 as well as NF-κB regulate TLR2 mRNA expression ( 44 ) and TLR9 mRNA is regulated by CRE/CREB ( 45 ), whereas transcription of TLR4 mRNA is mainly induced by NF-κB ( 46 ). Interestingly, mice deficient in TLR4 treated with apocynin did not show a better survival rate than WT mice after CLP (data not shown), which is in accordance with our previous data implicating TLRs in control of infection ( 21 , 47 ), which becomes irrelevant after the treatment of mice with antibiotics.…”